Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis

In subjects with normal renal function, acyclovir is rapidly removed from the body via the kidneys. In subjects with end-stage renal disease, the half-life is significantly prolonged. The half-life in subjects receiving hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) is similarly p...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacology Vol. 30; no. 11; p. 997
Main Authors Burgess, E D, Gill, M J
Format Journal Article
LanguageEnglish
Published England 01.11.1990
Subjects
Acyclovir - administration & dosage
Acyclovir - blood
Acyclovir - pharmacokinetics
Adult
Biological Availability
Half-Life
Humans
Injections, Intraperitoneal
Injections, Intravenous
Kidney Failure, Chronic - metabolism
Metabolic Clearance Rate
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory
Renal Dialysis
Online AccessGet more information

Cover

More Information
Summary:In subjects with normal renal function, acyclovir is rapidly removed from the body via the kidneys. In subjects with end-stage renal disease, the half-life is significantly prolonged. The half-life in subjects receiving hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) is similarly prolonged (10.0 +/- 2.2 and 13.2 +/- 4.7 hours, respectively). After intravenous dosage, peritoneal clearance was 3.4 +/- 0.2 mL/min. Intraperitoneal dosing in subjects receiving CAPD resulted in a bioavailability of 61 +/- 10% and drug levels sufficient to inhibit herpes simplex virus (HSV) and varicella zoster virus (VZV). Intraperitoneal administration is an alternative route of administration in patients with poor vascular access.
ISSN:0091-2700
DOI:10.1002/j.1552-4604.1990.tb03585.x